we have identified common genetic variations in receptors in the cardiovascular system that we believe interact with gencaro 's pharmacology and may predict patient response to the drug . we are testing this hypothesis in a phase 2b/3 clinical trial of gencaro , known as genetic-af . we are pursuing this indication for gencaro because data from the previously conducted phase 3 hf trial of gencaro in 2,708 heart failure , or hf , patients , or the best trial , which suggested that gencaro may be successful in reducing or preventing af . af is a disorder in which the normally regular and coordinated contraction pattern of the heart 's two small upper chambers , or the atria , becomes irregular and uncoordinated . the irregular contraction pattern associated with af causes blood to pool in the atria , predisposing the formation of clots potentially resulting in stroke . genetic-af is a phase 2b/3 multi-center , randomized , double-blind clinical trial comparing the safety and efficacy of gencaro to an active comparator , the beta-blocker toprol xl ( metoprolol succinate ) , in hfref patients with a current or recent history of paroxysmal ( af episodes lasting 7 days or less ) or persistent af who have a beta-1 389 arginine homozygous genotype , the genotype we believe responds most favorably to gencaro . the primary endpoint of genetic-af , time to recurrent symptomatic af/atrial flutter , or afl , or all-cause mortality , will be measured over a twenty-four week period after a patient has established a normal heart rhythm . we believe data from the best trial indicate that gencaro may have a genetically regulated effect in reducing or preventing af , whereas we believe the therapeutic benefit of toprol xl does not appear to be enhanced in patients with this genotype . a retrospective analysis of data from the best trial shows that the entire cohort of patients in the best trial treated with gencaro had a 41 % reduction in the risk of new onset af ( time-to-event ) compared to placebo ( p = 0.0004 ) . in the best dna substudy , patients with the beta-1 389 arginine homozygous genotype experienced a 74 % ( p = 0.0003 ) reduction in risk of af when receiving gencaro , based on the same analysis . the beta-1 389 arginine homozygous genotype was present in about 47 % of the patients in the best pharmacogenetic substudy , and we estimate it is present in about 50 % of the u.s. general population . we have created an adaptive design for genetic-af . we are seeking to enroll approximately 200 hfref patients in the phase 2b portion of the study who have recently experienced at least one episode of paroxysmal or persistent af and who have the beta-1 389 arginine homozygous genotype that we believe responds most favorably to gencaro . in addition to measuring the primary endpoint of recurrent symptomatic af/afl or all-cause mortality , an additional efficacy measure in the phase 2b portion of genetic-af will be af burden , defined as a patient 's percentage of time in af per day , regardless of symptoms . at least 150 patients in the phase 2b portion of the trial will have either a newly or previously implanted medtronic device that measures and records af burden . the genetic-af data safety monitoring board , or dsmb , will analyze certain data from the phase 2b portion of the trial and recommend based on a comparison to our pre-trial statistical assumptions , whether the trial should proceed to phase 3 and seek to enroll an additional 420 patients . the dsmb will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up , the period for measuring the trial 's primary end-point . the dsmb interim analysis will focus on available data regarding the primary end point , af/afl event rates , af burden , and safety . should the dsmb interim analysis conclude that the interim data is consistent with pre-trial statistical assumptions and indicates potential for achieving statistical significance for the phase 3 endpoint , the dsmb may recommend that the study proceed to phase 3. the dsmb may also recommend changes to the study design before the trial proceeds to phase 3 , or it may recommend that the study not proceed to phase 3. based on the dsmb recommendation , and other factors , including input from the trial 's steering committee , the company will make the final determination on the trial 's development steps . the full phase 2b/3 trial is designed for 90 percent power at a p-value of less than 0.01 significance level to detect a 25 percent reduction in the risk of af recurrence or death in patients in the gencaro arm compared to patients in the toprol xl arm . in consultation with the genetic-af steering committee , we implemented amendments to the trial protocol in march 2015 which we believe may expand the eligible target population , increase the patient screening and enrollment rate , and simplify trial procedures . we have undertaken these protocol amendments because patient enrollment in the trial has not met our original projections . under the revised protocol , patients in sinus rhythm who have experienced 37 symptomatic af in the past 120 days are now eligible for inclusion in the trial , as are patients with af episodes lasting 7 days or less , or paroxysmal af . previously , these patients were not eligible to be enrolled in the trial . story_separator_special_tag during the first half of 2013 , we incurred additional costs for our special proxy solicitation and shareholder meeting as part of our financing completed in june 2013. these activities and related costs were not recurring in 2014. g & a expenses in 2015 are expected to be higher than in 2014 as we increase administrative activities to support our genetic-af clinical trial . interest and other income interest and other income was $ 7,000 for the year ended december 31 , 2014 as compared to $ 5,000 for 2013 , resulting in an increase of $ 2,000. this is due to the increase in cash balances resulting from our february 2014 sale of equity securities . interest income was nominal in both years due to low investment yields . we expect interest income to continue to be nominal in 2015. interest and other expense interest and other expense was $ 3,000 for the year ended december 31 , 2014 , as compared to $ 4,000 for 2013. the amounts and related change between years are nominal to our overall operations . based on our current capital structure , interest expense for 2015 is expected to be comparable to 2014. liquidity and capital resources story_separator_special_tag preferred stock remained outstanding as all shares of the preferred stock had been converted into 12,500,000 shares of common stock . the warrants have an exercise price of $ 1.60 per share , will expire on the five year anniversary of the date of issuance , and were exercisable immediately upon issuance . our chief executive officer participated in the offering , purchasing 781 shares of preferred stock and warrants to purchase 39,050 shares of common stock . the securities were sold pursuant to a placement agreement and have been registered under the securities act of 1933 pursuant to the our registration statement on form s-1 , as amended ( no.333-187508 ) , which was declared effective by the securities and exchange commission on may 29 , 2013 , and the preferred stock and warrants were offered and sold pursuant to a prospectus dated may 30 , 2013. in connection with the preferred stock financing , the company recorded a non-cash dividend of approximately $ 2.0 million to recognize the intrinsic value of the embedded beneficial conversion feature . typically , such a deemed dividend would be represented as a reduction in a company 's retained earnings and an increase in additional paid in capital in recognition of the reapportionment of common shareholder value to the preferred stock purchasers . however , since we have an accumulated deficit , the deemed dividend is 40 recognized by a reapportionment of additional paid in capital from common shareholders to additional paid in capital of preferred stock purchasers , which are combined in the company 's statement of stockholders ' equity . these financings positioned us to initiate our genetic-af phase 2b/3 clinical trial during 2014. our ability to execute our genetic-af phase 2b trial in accordance with our projected time line depends on a number of factors , including , but not limited to , the following : recruitment of sufficient clinical trial sites , enrollment of patients and enrollment at a rate consistent with our projected timeline ; effects of protocol amendments and their projected impact on enrollment ; our ability to control costs associated with the clinical trial and our operations ; our ability to retain the listing of our common stock on the nasdaq capital market ; the market price of our stock and the availability and cost of additional equity capital from existing and potential new investors ; general economic and industry conditions affecting the availability and cost of capital ; the costs of filing , prosecuting , defending and enforcing any patent claims and other intellectual property rights ; and the terms and conditions of our existing collaborative and licensing agreements . in order to increase the pool of patients eligible for enrollment in genetic-af , consistent with the adaptive design nature of the trial , we consulted with the genetic-af steering committee and implemented amendments to the trial protocol in march 2015. we have undertaken these protocol amendments because patient enrollment in the trial has not met our original projections . under the revised protocol , patients in sinus rhythm who have experienced symptomatic af in the past 120 days are now eligible for inclusion in the trial , as are patients with paroxysmal af . previously , these patients were not eligible to be enrolled in the trial . based on the projected impact of this expanded patient population and the current enrollment rate , we now anticipate that the enrollment of 200 patients for the phase 2b portion of the trial may be completed by the end of 2016 , with the dsmb interim analysis finishing in the first half of 2017. we do not yet know how these protocol changes will impact enrollment or if our new enrollment projections will prove to be accurate . the sale of additional equity or convertible debt securities will be necessary for us to complete both phase 2b and phase 3 of the genetic-af clinical trial and submit for fda approval of gencaro . such financing would likely result in additional dilution to our existing stockholders . if we raise additional funds through the incurrence of indebtedness , the obligations related to such indebtedness would be senior to rights of holders of our capital stock and could contain covenants that would restrict our operations . we anticipate that our current cash and cash equivalents will be sufficient to fund our operations , at our projected cost structure , through the end of 2015 . however , our forecast of the period of time through which our financial resources will be adequate to support our current and forecasted operations could vary materially . critical accounting policies and estimates a critical accounting policy is one that is both important to the portrayal of our

cash and cash equivalents replace_table_token_4_th cash flows from operating , investing and financing activities replace_table_token_5_th net cash used in operating activities for the year ended december 31 , 2014 increased nearly $ 4.1 million compared with the 2013 period due to increased r & d and sg & a expenses discussed above . net cash provided by financing activities of approximately $ 8.0 million for the year ended december 31 , 2014 is comprised of approximately $ 7.9 million of net proceeds from the sales of our preferred and common stock and $ 0.3 million of proceeds from the exercise of warrants for cash , less $ 179,000 in payments made on a vendor financing arrangement . net cash provided by financing activities of approximately $ 19.2 million for the year ended december 31 , 2013 is comprised of approximately $ 19.3 million of net proceeds from the sales of our preferred and common stock , less $ 174,000 in payments made on a vendor financing arrangement . sources and uses of capital our primary sources of liquidity to date have been capital raised from issuances of shares of our preferred and common stock and funds provided by the merger with nuvelo . the primary uses of our capital resources to date have been to fund operating activities , including research , clinical development and drug manufacturing expenses , license payments , and spending on capital items . on february 3 , 2014 , we agreed to sell to certain investors an aggregate of 5,116,228 shares of our common stock and warrants to purchase an aggregate of 1,279,057 shares of our common stock at a purchase price of $ 1.70 per share of common stock , for aggregate 39 gross proceeds of approximately $ 8.7 million , before deducting placement agent fees and other offering related expenses . the offering closed on february 7 , 2014 , and the net proceeds to us were approximately $ 7.9 million . the common stock and warrants were sold in combination consisting of one share of common stock and a warrant to purchase 0.25 shares of common stock .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash and cash equivalents replace_table_token_4_th cash flows from operating , investing and financing activities replace_table_token_5_th net cash used in operating activities for the year ended december 31 , 2014 increased nearly $ 4.1 million compared with the 2013 period due to increased r & d and sg & a expenses discussed above . net cash provided by financing activities of approximately $ 8.0 million for the year ended december 31 , 2014 is comprised of approximately $ 7.9 million of net proceeds from the sales of our preferred and common stock and $ 0.3 million of proceeds from the exercise of warrants for cash , less $ 179,000 in payments made on a vendor financing arrangement . net cash provided by financing activities of approximately $ 19.2 million for the year ended december 31 , 2013 is comprised of approximately $ 19.3 million of net proceeds from the sales of our preferred and common stock , less $ 174,000 in payments made on a vendor financing arrangement . sources and uses of capital our primary sources of liquidity to date have been capital raised from issuances of shares of our preferred and common stock and funds provided by the merger with nuvelo . the primary uses of our capital resources to date have been to fund operating activities , including research , clinical development and drug manufacturing expenses , license payments , and spending on capital items . on february 3 , 2014 , we agreed to sell to certain investors an aggregate of 5,116,228 shares of our common stock and warrants to purchase an aggregate of 1,279,057 shares of our common stock at a purchase price of $ 1.70 per share of common stock , for aggregate 39 gross proceeds of approximately $ 8.7 million , before deducting placement agent fees and other offering related expenses . the offering closed on february 7 , 2014 , and the net proceeds to us were approximately $ 7.9 million . the common stock and warrants were sold in combination consisting of one share of common stock and a warrant to purchase 0.25 shares of common stock .
```    
 Suspicious Activity Report : we have identified common genetic variations in receptors in the cardiovascular system that we believe interact with gencaro 's pharmacology and may predict patient response to the drug . we are testing this hypothesis in a phase 2b/3 clinical trial of gencaro , known as genetic-af . we are pursuing this indication for gencaro because data from the previously conducted phase 3 hf trial of gencaro in 2,708 heart failure , or hf , patients , or the best trial , which suggested that gencaro may be successful in reducing or preventing af . af is a disorder in which the normally regular and coordinated contraction pattern of the heart 's two small upper chambers , or the atria , becomes irregular and uncoordinated . the irregular contraction pattern associated with af causes blood to pool in the atria , predisposing the formation of clots potentially resulting in stroke . genetic-af is a phase 2b/3 multi-center , randomized , double-blind clinical trial comparing the safety and efficacy of gencaro to an active comparator , the beta-blocker toprol xl ( metoprolol succinate ) , in hfref patients with a current or recent history of paroxysmal ( af episodes lasting 7 days or less ) or persistent af who have a beta-1 389 arginine homozygous genotype , the genotype we believe responds most favorably to gencaro . the primary endpoint of genetic-af , time to recurrent symptomatic af/atrial flutter , or afl , or all-cause mortality , will be measured over a twenty-four week period after a patient has established a normal heart rhythm . we believe data from the best trial indicate that gencaro may have a genetically regulated effect in reducing or preventing af , whereas we believe the therapeutic benefit of toprol xl does not appear to be enhanced in patients with this genotype . a retrospective analysis of data from the best trial shows that the entire cohort of patients in the best trial treated with gencaro had a 41 % reduction in the risk of new onset af ( time-to-event ) compared to placebo ( p = 0.0004 ) . in the best dna substudy , patients with the beta-1 389 arginine homozygous genotype experienced a 74 % ( p = 0.0003 ) reduction in risk of af when receiving gencaro , based on the same analysis . the beta-1 389 arginine homozygous genotype was present in about 47 % of the patients in the best pharmacogenetic substudy , and we estimate it is present in about 50 % of the u.s. general population . we have created an adaptive design for genetic-af . we are seeking to enroll approximately 200 hfref patients in the phase 2b portion of the study who have recently experienced at least one episode of paroxysmal or persistent af and who have the beta-1 389 arginine homozygous genotype that we believe responds most favorably to gencaro . in addition to measuring the primary endpoint of recurrent symptomatic af/afl or all-cause mortality , an additional efficacy measure in the phase 2b portion of genetic-af will be af burden , defined as a patient 's percentage of time in af per day , regardless of symptoms . at least 150 patients in the phase 2b portion of the trial will have either a newly or previously implanted medtronic device that measures and records af burden . the genetic-af data safety monitoring board , or dsmb , will analyze certain data from the phase 2b portion of the trial and recommend based on a comparison to our pre-trial statistical assumptions , whether the trial should proceed to phase 3 and seek to enroll an additional 420 patients . the dsmb will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up , the period for measuring the trial 's primary end-point . the dsmb interim analysis will focus on available data regarding the primary end point , af/afl event rates , af burden , and safety . should the dsmb interim analysis conclude that the interim data is consistent with pre-trial statistical assumptions and indicates potential for achieving statistical significance for the phase 3 endpoint , the dsmb may recommend that the study proceed to phase 3. the dsmb may also recommend changes to the study design before the trial proceeds to phase 3 , or it may recommend that the study not proceed to phase 3. based on the dsmb recommendation , and other factors , including input from the trial 's steering committee , the company will make the final determination on the trial 's development steps . the full phase 2b/3 trial is designed for 90 percent power at a p-value of less than 0.01 significance level to detect a 25 percent reduction in the risk of af recurrence or death in patients in the gencaro arm compared to patients in the toprol xl arm . in consultation with the genetic-af steering committee , we implemented amendments to the trial protocol in march 2015 which we believe may expand the eligible target population , increase the patient screening and enrollment rate , and simplify trial procedures . we have undertaken these protocol amendments because patient enrollment in the trial has not met our original projections . under the revised protocol , patients in sinus rhythm who have experienced 37 symptomatic af in the past 120 days are now eligible for inclusion in the trial , as are patients with af episodes lasting 7 days or less , or paroxysmal af . previously , these patients were not eligible to be enrolled in the trial . story_separator_special_tag during the first half of 2013 , we incurred additional costs for our special proxy solicitation and shareholder meeting as part of our financing completed in june 2013. these activities and related costs were not recurring in 2014. g & a expenses in 2015 are expected to be higher than in 2014 as we increase administrative activities to support our genetic-af clinical trial . interest and other income interest and other income was $ 7,000 for the year ended december 31 , 2014 as compared to $ 5,000 for 2013 , resulting in an increase of $ 2,000. this is due to the increase in cash balances resulting from our february 2014 sale of equity securities . interest income was nominal in both years due to low investment yields . we expect interest income to continue to be nominal in 2015. interest and other expense interest and other expense was $ 3,000 for the year ended december 31 , 2014 , as compared to $ 4,000 for 2013. the amounts and related change between years are nominal to our overall operations . based on our current capital structure , interest expense for 2015 is expected to be comparable to 2014. liquidity and capital resources story_separator_special_tag preferred stock remained outstanding as all shares of the preferred stock had been converted into 12,500,000 shares of common stock . the warrants have an exercise price of $ 1.60 per share , will expire on the five year anniversary of the date of issuance , and were exercisable immediately upon issuance . our chief executive officer participated in the offering , purchasing 781 shares of preferred stock and warrants to purchase 39,050 shares of common stock . the securities were sold pursuant to a placement agreement and have been registered under the securities act of 1933 pursuant to the our registration statement on form s-1 , as amended ( no.333-187508 ) , which was declared effective by the securities and exchange commission on may 29 , 2013 , and the preferred stock and warrants were offered and sold pursuant to a prospectus dated may 30 , 2013. in connection with the preferred stock financing , the company recorded a non-cash dividend of approximately $ 2.0 million to recognize the intrinsic value of the embedded beneficial conversion feature . typically , such a deemed dividend would be represented as a reduction in a company 's retained earnings and an increase in additional paid in capital in recognition of the reapportionment of common shareholder value to the preferred stock purchasers . however , since we have an accumulated deficit , the deemed dividend is 40 recognized by a reapportionment of additional paid in capital from common shareholders to additional paid in capital of preferred stock purchasers , which are combined in the company 's statement of stockholders ' equity . these financings positioned us to initiate our genetic-af phase 2b/3 clinical trial during 2014. our ability to execute our genetic-af phase 2b trial in accordance with our projected time line depends on a number of factors , including , but not limited to , the following : recruitment of sufficient clinical trial sites , enrollment of patients and enrollment at a rate consistent with our projected timeline ; effects of protocol amendments and their projected impact on enrollment ; our ability to control costs associated with the clinical trial and our operations ; our ability to retain the listing of our common stock on the nasdaq capital market ; the market price of our stock and the availability and cost of additional equity capital from existing and potential new investors ; general economic and industry conditions affecting the availability and cost of capital ; the costs of filing , prosecuting , defending and enforcing any patent claims and other intellectual property rights ; and the terms and conditions of our existing collaborative and licensing agreements . in order to increase the pool of patients eligible for enrollment in genetic-af , consistent with the adaptive design nature of the trial , we consulted with the genetic-af steering committee and implemented amendments to the trial protocol in march 2015. we have undertaken these protocol amendments because patient enrollment in the trial has not met our original projections . under the revised protocol , patients in sinus rhythm who have experienced symptomatic af in the past 120 days are now eligible for inclusion in the trial , as are patients with paroxysmal af . previously , these patients were not eligible to be enrolled in the trial . based on the projected impact of this expanded patient population and the current enrollment rate , we now anticipate that the enrollment of 200 patients for the phase 2b portion of the trial may be completed by the end of 2016 , with the dsmb interim analysis finishing in the first half of 2017. we do not yet know how these protocol changes will impact enrollment or if our new enrollment projections will prove to be accurate . the sale of additional equity or convertible debt securities will be necessary for us to complete both phase 2b and phase 3 of the genetic-af clinical trial and submit for fda approval of gencaro . such financing would likely result in additional dilution to our existing stockholders . if we raise additional funds through the incurrence of indebtedness , the obligations related to such indebtedness would be senior to rights of holders of our capital stock and could contain covenants that would restrict our operations . we anticipate that our current cash and cash equivalents will be sufficient to fund our operations , at our projected cost structure , through the end of 2015 . however , our forecast of the period of time through which our financial resources will be adequate to support our current and forecasted operations could vary materially . critical accounting policies and estimates a critical accounting policy is one that is both important to the portrayal of our

